Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced ...
Immunic, Inc. to Participate in Scientific and Industry Conferences in April ...
Immunic (IMUX – Research Report) received a Buy rating and a $1.20 price target from William Blair analyst Matt Phipps yesterday. The company’s ...
Fintel reports that on March 25, 2025, William Blair initiated coverage of Immunic (NasdaqGS:IMUX) with a Outperform ...
So should Immunic (NASDAQ:IMUX) shareholders be worried about its cash burn? In this article, we define cash burn as its annual (negative) free cash flow, which is the amount of money a company ...
Immunic (NASDAQ:IMUX – Get Free Report) was downgraded by equities research analysts at StockNews.com from a “hold” rating to ...
Analysts at William Blair issued their FY2026 EPS estimates for shares of Immunic in a research note issued to investors on ...
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com ...
The firm increased its portfolio allocation in IMUX by 12.46% over the last quarter. Soleus Capital Management holds 7,293K shares representing 8.10% ownership of the company. No change in the ...
Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback